The second therapeutic trial for children with hematological malignancies who relapsed after their first allogeneic SCT: Long-term outcomes

Takuro Nishikawa, Jiro Inagaki, Yoshihisa Nagatoshi, Reiji Fukano, kentaro nakashima, Nobuhiro Ito, Daisuke Sawa, Yoshifumi Kawano, Jun Okamura

Research output: Contribution to journalReview article

3 Citations (Scopus)

Abstract

The impact of a second all-SCT on the long-term outcomes of children who relapse after allo-SCT has been unclear. We retrospectively analyzed the long-term outcomes of different salvage treatments for such children. Sixty-six children with hematological malignancies (40 ALL, 22 AML, three MDS, and one CML) who relapsed after a first allo-SCT received either a second allo-SCT (n = 16) or CTx and/or DLI (n = 50). The median follow-up for all children was 9.1 yr. The five-yr OS after relapse was significantly better in patients who underwent a second allo-SCT (42.9%) than in patients treated with CTx and/or DLI (11.8%) (p < 0.05). However, this advantage diminished with increasing time. The eight-yr OS for these groups of patients were 21.4% and 11.8%, respectively (p = n.s.). Among the 16 patients who received a second allo-SCT, two died more than five yr after the second allo-SCT. A second allo-SCT can therefore lead to a prolonged OS in patients who relapse after allo-SCT. However, a second allo-SCT should be selected carefully. This is because the mortality rate is still high, even when there is an extensive duration of time following the second allo-SCT.

Original languageEnglish
Pages (from-to)722-728
Number of pages7
JournalPediatric Transplantation
Volume16
Issue number7
DOIs
Publication statusPublished - Nov 1 2012

All Science Journal Classification (ASJC) codes

  • Pediatrics, Perinatology, and Child Health
  • Transplantation

Fingerprint Dive into the research topics of 'The second therapeutic trial for children with hematological malignancies who relapsed after their first allogeneic SCT: Long-term outcomes'. Together they form a unique fingerprint.

  • Cite this

    Nishikawa, T., Inagaki, J., Nagatoshi, Y., Fukano, R., nakashima, K., Ito, N., Sawa, D., Kawano, Y., & Okamura, J. (2012). The second therapeutic trial for children with hematological malignancies who relapsed after their first allogeneic SCT: Long-term outcomes. Pediatric Transplantation, 16(7), 722-728. https://doi.org/10.1111/j.1399-3046.2012.01737.x